These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease? Vanacore N Neuroepidemiology; 2010; 35(3):213. PubMed ID: 20664294 [No Abstract] [Full Text] [Related]
6. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Rascol O Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315 [TBL] [Abstract][Full Text] [Related]
7. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotection in Parkinson's disease: an elusive goal. Biglan KM; Ravina B Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255 [TBL] [Abstract][Full Text] [Related]
10. Designing neuroprotection trials in Parkinson's disease. Kieburtz K Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102 [TBL] [Abstract][Full Text] [Related]
11. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Montgomery EB Neurology; 2010 Nov; 75(21):1943; author reply 1944-5. PubMed ID: 21155188 [No Abstract] [Full Text] [Related]
12. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Schwarzschild MA Neurology; 2010 Nov; 75(21):1943-4; author reply 1944-5. PubMed ID: 21098412 [No Abstract] [Full Text] [Related]
13. [The early therapy challenge]. Reichmann H Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310 [No Abstract] [Full Text] [Related]
14. Designing and funding clinical trials of novel therapies. Antman K; Lagakos S; Drazen J N Engl J Med; 2001 Mar; 344(10):762-3. PubMed ID: 11236782 [No Abstract] [Full Text] [Related]
15. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Clarke CE Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811 [TBL] [Abstract][Full Text] [Related]
16. The value of clinical wisdom in randomised studies, real-world registries and new hypotheses. Bernardi G; Morocutti G; Spedicato L; Zanuttini D J Cardiovasc Med (Hagerstown); 2007 May; 8(5):313-7. PubMed ID: 17443094 [No Abstract] [Full Text] [Related]
17. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106 [No Abstract] [Full Text] [Related]
18. Neuroprotective trials: no longer a cautious optimism. Friedman JH Med Health R I; 2008 Jun; 91(6):158. PubMed ID: 18610798 [No Abstract] [Full Text] [Related]